Risankizumab for Crohn's disease

This publication has 11 references indexed in Scilit:

• Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
  The Lancet, 2022
• Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
  Gastroenterology, 2022
• Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn’s Disease
  Gastroenterology, 2022
• 775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study
  Gastroenterology, 2021
• Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials
  Clinical Pharmacokinetics, 2018
• Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
  The Lancet, 2017
• Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
  New England Journal of Medicine, 2016
• Interleukin 23 in Crohnʼs Disease
  Inflammatory Bowel Diseases, 2014
• IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease
  Gut, 2008
• A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
  Science, 2006